Axicabtagene ciloleucel is Kite's investigational therapy treatment, formerly referred to as KTE-C19, that is targeted towards patients of leukemia and varying forms of lymphoma. Some such lymphoma patients are those who are unable to receive autologous stem cell transplants but do have transformed follicular lymphoma (TFL), relapsed or refractory diffuse large B-cell lymphoma (DLBCL), or primary mediastinal B-cell lymphoma (PMBCL). It is a CAR T-cell therapy that amasses a patient's preexisting T-cells in order to modify them. In this modification, patient's T-cells are transformed to depict a CAR protein. This protein identifies the molecule CD19 (a surface protein) that is seen in leukemias and B-cell lymphomas.